

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/EP2006/002172

International filing date: 09 March 2006 (09.03.2006)

Document type: Certified copy of priority document

Document details: Country/Office: EP  
Number: 05005390.9  
Filing date: 11 March 2005 (11.03.2005)

Date of receipt at the International Bureau: 20 June 2006 (20.06.2006)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

PCT/EP200 6/ 0 0 2 1 7 2  
09-03-06



Europäisches  
Patentamt

European  
Patent Office

Office européen  
des brevets

Bescheinigung

Certificate

Attestation

Die angehefteten Unterla-  
gen stimmen mit der  
ursprünglich eingereichten  
Fassung der auf dem näch-  
sten Blatt bezeichneten  
europäischen Patentanmel-  
dung überein.

The attached documents  
are exact copies of the  
European patent application  
described on the following  
page, as originally filed.

Les documents fixés à  
cette attestation sont  
conformes à la version  
initialement déposée de  
la demande de brevet  
européen spécifiée à la  
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

05005390.9

Der Präsident des Europäischen Patentamts;  
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets  
p.o.

R C van Dijk

Europäisches  
PatentamtEuropean  
Patent OfficeOffice européen  
des brevets

PCT/EP200 6/ 0 0 2 1 7 2

09.03.06

Anmeldung Nr:

Application no.: 05005390.9

Demande no:

Anmeldetag:

Date of filing: 11.03.05

Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

AXXAM S.r.l.  
Via Massena, 12/7  
20145 Milano  
ITALIE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:

(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.

If no title is shown please refer to the description.

Si aucun titre n'est indiqué se référer à la description.)

Photoproteins with enhanced bioluminescence and assays using the same

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)  
revendiquée(s)

Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/  
Classification internationale des brevets:

C07K14/00

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of  
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU  
MC NL PL PT RO SE SI SK TR LI

**PHOTOPROTEINS WITH ENHANCED BIOLUMINESCENCE AND  
ASSAYS USING THE SAME**

The present invention relates to photoproteins with enhanced bioluminescence and to their use as intracellular calcium indicators. The photoproteins are obtained by mutagenesis of the clytin coding sequence and show enhanced bioluminescence, high affinity for calcium and long-lasting  
5 light emission. They are conveniently used in cell-based assays to determine variations of intracellular calcium concentration, particularly in assays for the screening of molecules with high and ultra-high-throughput techniques.

**BACKGROUND OF THE INVENTION**

Bioluminescence is the phenomenon by which visible light is emitted  
10 by living organisms or by a substance derived from them through a variety of chemiluminescent reaction systems. Bioluminescence reactions require three major components: a luciferin, a luciferase and molecular oxygen. However, other components may also be required in some reactions, including cations ( $\text{Ca}^{++}$  and  $\text{Mg}^{++}$ ) and cofactors (ATP, NAD(P)H). Luciferases are enzymes that  
15 catalyse the oxidation of a substrate, luciferin, and produce an unstable intermediate. Light is emitted when the unstable intermediate decays to its ground state, generating oxyluciferin. There are many different unrelated types of luciferin, although many species from at least seven phyla use the same luciferin, known as coelenterazine. In some animals (e.g. jellyfish) the  
20 luciferin/luciferase system can be extracted in the form of a stable "photoprotein" which emits light upon calcium binding. Photoproteins differ from luciferases in that they are stabilized oxygenated intermediate complexes of luciferase and luciferin. Photoproteins are present in many marine coelenterates and allow these organisms to emit light for a variety of purposes  
25 including breeding, feeding and defense (1). There are many luminescent

organisms, but only seven photoproteins, namely Thalassicolin (2,3), Aequorin (4-6), Mitrocomin (syn. with Halistaurin) (7,8), Clytin (syn. with Phialidin) (8,9), Obelin (2,6,10,11), Mnemiopsin (12,13) and Berovin (12,13) have been isolated so far. All these proteins are complexes formed by an apoprotein, an imidazopyrazine chromophore (coelenterazine) and oxygen. Their structures are highly conserved, especially in the region containing the three calcium binding sites (EF-hand structures). The term "photoprotein" identifies the luciferin-bound polypeptide, which is capable of luminescence, while "apophotoprotein" is used to indicate the protein without luciferin.

The most studied photoproteins are Aequorin, isolated from *Aequorea victoria* (14) and Obelin, isolated from *Obelia longissima* (15). The photoprotein may be regenerated from the apophotoprotein by incubation with coelenterazine, molecular oxygen, EDTA and 2-mercaptoethanol or dithiothreitol. Since coelenterazine is the common luminescent substrate used by the photoproteins Aequorin, Mitrocomin, Clytin and Obelin, the light-emitting reaction is likely the same in these four photoproteins (16,17).

The Clytin photoprotein was cloned in 1993 by Inouye et al. (18). To date not much work has been done on this photoprotein. The primary structures of aequorin, mitrocomin, clytin and obelin were aligned and showed very strong amino acid sequence identities. The  $\text{Ca}^{2+}$ -binding sites of Clytin were also found to be highly conserved (19). It was found that hydrozoan  $\text{Ca}^{2+}$ -binding photoprotein differs from other  $\text{Ca}^{2+}$ -binding proteins such as calmodulin and troponin C by a relatively high content of cysteine, histidine, tryptophan, proline and tyrosine residues.

The analysis of the primary structure of clytin shows that it contains 198 aminoacidic residues (aa) and belongs to the family of photoproteins.

Photoproteins are widely used in reporter gene technology to monitor the cellular events associated with signal transduction and gene expression.

The study of cellular events and their regulation requires sensitive, non invasive analytic methods. Photoproteins and in general the use of bioluminescence are excellent reporter systems as they have virtually no background in contrast to fluorescence systems.

5 Photoproteins are expressed in mammalian cells to monitor calcium changes in response to different stimuli. Intracellular calcium concentrations can be measured by adding the cofactor coelenterazine to mammalian cells expressing the photoprotein and detecting photon emission, which is indicative of intracellular calcium concentration. The use of cells which  
10 express both a photoprotein and a receptor involved in the modulation of intracellular calcium concentration provides a valid system for the screening of compounds for their effects on the release of intracellular calcium. High throughput screening assays can also be designed using a photoprotein as reporter system. The sensitivity of the system as well as its high signal to  
15 noise ratio allow the use of small assay-volumes. Aequorin is up to now the most used photoprotein for these screening assays.

Calcium flux assays are commonly carried out in HTS format utilizing optical screening apparatuses suited for the simultaneous analysis of a high number of samples and equipped with a luminescence imaging system with a  
20 CCD Camera detector. However, one of the most used instruments in HTS is FLIPR® (Fluorometric Imaging Plate Reader, Molecular Devices Corporation, Sunnyvale, CA, USA) which was developed as a high throughput optical screening tool for cell-based fluorescent assays. The apparatus is equipped with an optical detection device that allows for signal isolation on a  
25 cell-monolayer, thereby enhancing sensitivity for cell-based assays. The excitation source can be either an Argon laser or a broadband source as a Xenon lamp.

With a light-tight enclosure, extremely sensitive and fast camera, and

true simultaneous on-line liquid dispensing, the FLIPR<sup>®</sup> system most recent versions (FLIPR<sup>3</sup> and FLIPR<sup>TETRA</sup>) have been made suitable also for luminescence assays, even if with lower sensitivity compared to CCD Camera-based equipments.

5 For the use of the above described instruments FLIPR<sup>®</sup>, FLIPR<sup>3</sup> and FLIPR<sup>TETRA</sup> and in general for all instruments with a low sensitivity for luminescence assays, a photoprotein with enhanced light emission is highly desirable.

### DISCLOSURE OF THE INVENTION

10 According to a first aspect, the invention provides an isolated photoprotein containing an amino acid sequence which:

- a) is able to bind coelenterazine and calcium, producing bioluminescence;
- b) has an identity of at least 90%, preferably of at least 95%, more preferably of at least 98% to SEQ ID NO: 1 (Clytin);
- 15 c) in sequence alignment with SEQ ID 1 (Clytin), presents one of the following single or multiple substitutions (the residue positions are referred to SEQ ID NO: 1):
  - i) C<sub>54</sub>→S;
  - 20 ii) S<sub>132</sub>→C;
  - iii) K<sub>48</sub>→R, N<sub>195</sub>→D;
  - iv) Q<sub>68</sub>→R, A<sub>90</sub>→V, T<sub>184</sub>→I;
  - v) Y<sub>82</sub>→F, K<sub>110</sub>→N, F<sub>125</sub>→L, S<sub>149</sub>→R;
  - vi) G<sub>142</sub>→C;
  - 25 vii) I<sub>53</sub>→V, S<sub>149</sub>→R;
  - viii) N<sub>18</sub>→D, I<sub>40</sub>→V, K<sub>56</sub>→R

In a preferred embodiment, the photoprotein contains an amino acid sequence which is selected from the group of SEQ ID NO: 2, 3, 4, 5, 6, 7, 8



and 9. Compared to known or commercially available photoproteins, the photoproteins of the invention show improved bioluminescence activity, higher affinity to calcium and longer-lasting light emission.

5 Apart from the indicated residue-substitutions, which confer the desired photoprotein bioluminescence activity, the Clytin sequence can be further modified without negatively affecting the photoprotein's bioluminescence activity, especially by conservative substitutions of amino acidic residues, within the indicated sequence-identity limits. In addition, the Clytin sequence can be deleted of small portions, without altering its photoprotein activity.

10 In a further aspect, the invention is directed to a polynucleotide encoding a photoprotein as defined above. In a preferred embodiment, the polynucleotide sequences are optimized for mammalian codon usage according to SEQ ID NO: 10, 11, 12, 13, 14, 15, 16, 17. In a further preferred embodiment, the nucleic acid molecules are fused to mitochondrial target  
15 sequences (20, 21, 22).

According to a further aspect, the invention provides expression vectors and host cells containing the indicated polynucleotides. Host cells expressing a photoprotein according to the invention produce an intense bioluminescence in response to calcium stimulation, which is much higher than that observed  
20 with natural photoproteins, in particular with the most used one, Aequorin.

In a further aspect, the invention provides a cell-based assay for determining intracellular calcium concentration by means of a photoprotein according to the invention.

In a preferred embodiment, the changes in intracellular calcium  
25 concentration are determined by:

- a) providing a cell expressing a photoprotein of SEQ ID NO: 2-9, variants or fragments thereof;
- b) loading of the cells with coelenterazine;



- c) contacting the cells with an agent stimulating calcium influx or calcium release from intracellular stores;
- d) detecting the photoprotein's bioluminescence.

The assay is preferably carried out in a high-throughput format utilizing  
5 an optical screening tool or apparatus suited for multi-sample analysis, such as  
a luminescence imaging system with a CCD Camera detector for high and  
ultra high throughput applications, or with the Fluorometric Imaging Plate  
Reader (FLIPR®). With both these systems, the photoproteins of the invention  
10 produce the highest signal compared to known photoproteins commonly used  
in automatized cell functional assays.

In a preferred embodiment, cells expressing a photoprotein and a  
receptor involved in intracellular calcium mobilization are used to test  
candidate molecules for their effects on receptor modulation. Typically, cells  
are transfected with an expression vector containing a photoprotein encoding  
15 sequence and when not endogenously present, a receptor or channel of  
interest. The positive clones are selected and plated in a suitable medium,  
cultured cells are loaded with the coelenterazine substrate and the assay is  
started by adding the test molecule or stimulus. The produced luminescence is  
read by a suitable detection system (CCD camera or luminometer). The assay  
20 can also be run in an automatic apparatus equipped with multi-well plate  
reading, in particular the FLIPR® system. In this case, photoprotein-expressing  
cells are plated in microplate wells, which, after addition of the test  
molecule/stimulus, are read simultaneously with signal recording.

High throughput screening assays set up with a photoprotein-based  
25 reporter system show improved sensitivity and signal-to-noise ratio. Cells  
expressing a photoprotein of the invention produce an intense  
bioluminescence in response to calcium stimulation, which is generally higher  
than that observed with natural photoproteins.

In a further aspect, the invention provides an assay kit containing a preparation of cells expressing an invention photoprotein under the control of a stable or inducible promoter, and reagents suitable for running the assay.

In addition, the photoproteins of the invention may be used as  
5 intracellular calcium indicators in diagnostic methods based on the measurement of cellular calcium ion concentration and/or cellular calcium ion influx/outflow.

The invention will be described in more detail in the following experimental section.

## 10 MATERIALS AND METHODS

### Reagents

Restriction enzymes were purchased from New England Biolabs and used according to supplier's instructions. The Ligation Independent Cloning (LIC) kit was from Novagen (Nottingham, UK). For *in vitro* Transcription and  
15 Translation we used the TNT Quick coupled kit from Promega (Madison, WI). Reagents for PCR, and competent cells of *E. coli* strains XL-1Blue and BL21-Gold(DE3), were from Stratagene (La Jolla, CA). Oligonucleotides were purchased from Primm (Milan). Coelenterazine was from Pharma Tech. International Inc. (Fairfield, NJ). All other chemicals were from standard  
20 sources and were of reagent grade or better.

### 1. Generation of a Randomly Mutagenized Library and Screening

#### 1.1 Photoprotein optimization for expression in mammalian cells (GENEART GmbH, Regensburg, Germany)

The codon usage of the wild-type clytin gene was adapted to the codon  
25 bias of highly expressed mammalian genes. In addition regions of very high (> 80%) or very low (< 30%) GC content have been avoided where possible.

For efficient translation initiation the Kozak-consensus sequence was introduced upstream of the start codon. Two STOP codons were added to

ensure efficient termination.

### 1.2 Random Mutagenesis

The GeneMorph II Random Mutagenesis kit (Stratagene) was used following supplier's instructions. Two different initial amounts of target DNA were used to achieve a high mutation rate, 0.1ng and 0.01ng.

PCR primers were appropriately designed to contain 5' LIC extensions (in italics) corresponding to sequences described in the Ek/LIC Cloning Kit (Novagen).

Upper: *GATGACGACGACAAG*-ATGGCCGACACCGCCAG

Lower: *GAGGAGAAGCCCGGT*-TTATCAAGGACACGAAGT

Amplification protocol performed in the Perkin Elmer 2400 thermocycler:

1 time the following step:

pre PCR 2' at 94°C

30 times the following steps:

denaturation 30'' at 94°C

annealing 30'' at 56°C

elongation 40'' at 72°C

1 time the following step:

elongation 10' at 72°C

Expected length of specific PCR product: 630 bp.

To quantitatively determine the amount of DNA obtained, amplification products were analysed by electrophoresis on 1% agarose gel in 1xTAE running buffer following standard procedure, as described by Maniatis et al.

The samples were compared to a DNA molecular weight marker (MWXVI, Roche).

### 1.3 Ek/LIC Cloning

The Novagen Ligation Independent Cloning (LIC) kit was used

following suppliers instructions in order to obtain directional cloning of the PCR products without the need of restriction enzyme digestion or ligation reactions. The pET-30 Ek/LIC vector, engineered to express the target protein immediately downstream of an enterokinase cleavage site, was chosen.

#### 1.4 Transformation

For good protein expression we chose BL21-Gold(DE3) cells (Stratagene), a derivative of E.coli B, an improved strain of BL21 competent cells. The genotype of the strain is: E.coli B  $F^-$  *ompT* *hsdS* ( $r_B^-$   $m_B^-$ )  $dcm^+$   $Tet^r$  gal  $\lambda$ (DE3) *endA* *Hte*.

This strain lacks both the *lon* and the *ompT* proteases, which can degrade proteins during purification. *Hte* phenotype increases the transformation efficiency ( $>1 \times 10^8$  cfu/ $\mu$ g of pUC18 DNA) In addition the *endA* gene, that encodes endonuclease I is inactivated (no degradation of plasmid DNA).

In order to obtain competent cells with a high efficiency of transformation, we followed the standard protocol for preparing and electro-transforming BL21-Gold(DE3) cells described in the E. coli Pulser Transformation apparatus manual (BioRad).

Transformation efficiency was tested by using the pUC18 DNA and the pET DNA vectors and the efficiencies obtained were:

- $1 \times 10^{10}$  cfu/ $\mu$ g of pUC18 DNA
- $1 \times 10^8$  cfu/ $\mu$ g of pET DNA

Using these highly electrocompetent cells we were able to obtain a library of approximately 84,000 colonies expressing the randomly mutated Clytin photoprotein.

#### 1.5 Plating, induction and charging

Transformed cells were plated on an LB agar plates and grown overnight at 37°C. After overnight colony growth, induction was obtained by

adding 10 mM IPTG and 5 mM EDTA, and incubating for 4 hours at 37°C. Colonies were charged with 10 µM Coelenterazine solution and incubated overnight at 4°C in the absence of light.

#### 1.6 CCD camera measurement

5 Bioluminescence is assayed by the detection of the signal over a fixed time period of 30'' at time 0, after 3 and after 5 minutes from the first measurement.

#### 1.7 Colony picking and re-testing

10 The best colonies were picked and grown in 1ml of LB liquid medium and re-tested using the same experimental conditions described before.

#### 2. *In vitro* transcription and translation

15 Translation of the photoproteins was carried out in the rabbit reticulocyte cell-free system (TNT Quick coupled kit, Promega), following the general instructions of the supplier. 500 ng of DNA was used for each *in vitro* transcription/translation reaction mix. The reaction volume (10 µl) included 8 µl of TNT T7 Quick Master Mix, 1.6 µl of DNA, 0.2 µl of the Methionine buffer and 0.2 µl of Coelenterazine (0.5 mM). To this end, 5 µl from each sample of the translation mixture were tested for light emission by the injection of calcium solution and by measuring at the Ascent Luminoskan (Labsystems).

#### 20 3. Recombinant protein production

For the production of the recombinant protein we followed a small scale protein purification protocol under native conditions. Due to the presence of an N-terminal His tag in our constructs, we decided to purify the expressed proteins on Ni-NTA Spin Columns (Qiagen) following the suppliers' protocol.

#### 25 4. Calcium concentration curve

In order to evaluate the response of the photoprotein to different calcium concentrations, 0,05 ng/well (96 MTP) of the recombinant protein were charged with Coelenterazine 10 µM overnight at 4°C.

After incubation, different concentrations of  $\text{CaCl}_2$  were injected and the light released was measured at the Ascent Luminoskan with an integration time of 20 ms for a total time of 10 seconds.

### 5. Expression of the mutant photoprotein in mammalian cells

#### 5 Reagents

Restriction enzymes were purchased from New England Biolabs (Beverly, MA) and used according to supplier's instructions. Rapid DNA ligation kit and Eugene transfection reagent were purchased from Roche (Basel, CH). Coelenterazine was from Pharma Tech. International Inc. (Fairfield, NJ). All other chemicals were from standard sources and were of reagent grade or better.

#### Cloning procedure

The most promising mutant photoprotein clones were subcloned for testing their expression in mammalian cells.

15 2  $\mu\text{l}$  of plasmid were used as template in PCR analysis. In addition a negative control was performed with no template.

Standard PCR procedure were as indicated by Perkin Elmer. PCR protocol was as follows:

#### Primers:

20 Upper primer: TCGTTGGGATCCGCCACCATGGCCGACACCGCC

Lower primer: GGGCCCTCTAGATTATCAAGGCACGAA

#### PCR reaction mix:

2  $\mu\text{l}$  template

5  $\mu\text{l}$  10 x Pfx Buffer (GIBCO-LifeTechnologies)

25 1.5  $\mu\text{l}$  10 mM dNTPs

1  $\mu\text{l}$  50 mM  $\text{MgSO}_4$  (GIBCO-LifeTechnologies)

2.5  $\mu\text{l}$  upper primer (10  $\mu\text{M}$ )

2.5  $\mu\text{l}$  lower primer (10  $\mu\text{M}$ )



2.5 U Platinum Pfx (GIBCO-LifeTechnologies)

35 µl H<sub>2</sub>O

Amplification protocol performed in Perkin Elmer 2400 thermocycler:

1 time the following step:

5 pre PCR 2' at 94°C

25 times the following steps:

denaturation 15'' at 94°C

annealing 30'' at 56°C

elongation 40'' at 68°C

10 1 time the following step:

elongation 10' at 68°C

Expected length of specific PCR product: 630 bp.

Amplification products were analysed by electrophoresis on 1% agarose gel in 1xTAE running buffer following the standard procedure, as described  
15 by Maniatis et al.

The PCR product was gel purified using Qiagen columns and digested with BamHI and XbaI restriction enzymes.

*pcDNA3neo-/mitoMutated-clytin construction.*

An in-house modified pcDNA3 vector (Invitrogen) has been prepared  
20 containing the sequence encoding the mitochondrial targeting peptide from subunit VIII of human cytochrome c oxidase (20, 21, 22) so that it could be used in frame at the 5' end of the codon-usage optimized photoprotein gene. The amplification product obtained from the above mentioned PCR has been cloned into this modified pcDNA3 vector lacking the Neomycin resistance  
25 gene for expression in mammalian cell lines.

For the mitochondrial targeting the signal sequence is:

5'-ATGTCCGTCCTGACGCCGCTGCTGCTGCGGGGCTTGACAGGCTCGGC  
CCGGCGGCTCCCAGTGCCGCGCGCCAAGATCCATTCGTTGGGATCCGCCACC-3'.

*pcDNA3neo-/cytoMutated-clytin construction*

The Mutated-clytin gene is obtained from the pcrScript/hMutated-clytin vector by digestion with BamHI and XbaI. The pcDNA3neo- is digested with the BamHI and XbaI restriction enzymes, and purified.

5 The Mutated-clytin gene is then ligated into the pcDNA3neo- vector to obtain pcDNA3neo-CYTO-hMutated-clytin.

Both constructs obtained were verified by full-length dideoxy sequencing.

**Cell culture**

10 Culture medium, seeding and incubation: DMEM/F12 with Glutamax (GIBCO cod. 31331-028), 10% FBS, 1% Pen./Strep. (Invitrogen cod. 15140-122), 25 mM Hepes Buffer Solution (GIBCO cod. 15630-056), 1.0 mM Sodium Pyruvate (GIBCO cod. 11360-039), 1.5 g/L Sodium Bicarbonate (GIBCO cod. 25080-060).

15 Preculture conditions: Cells were seeded for experiments when 70-80% confluent.

Cell culture conditions: Split twice a week:  $3.0 \times 10^5$  cells/flask T75 (recovery:  $8 \times 10^6$  cells).

Clone Selection Process:

- 20
- CHO-K1 were transfected with pcDNA3Neo-/MITO-hMutated-clytin.
  - 48 h after transfection, the transfected cells were plated in 10x96 w/p in complete DMEM.
  - At confluence the 10x96 w/p were duplicated in 10 white plates. 3 ½ hours before measurements, medium was replaced with 50 µl/well of
- 25 tyrode (2 mM  $\text{Ca}^{2+}$  and coelenterazine 10 µM).
- Positive clones were selected evaluating:
  - First selection was done lysing cells with TRITON X-100. CCD camera conditions: low sensitivity, integration time 1 second reading

for 5 seconds.

- Five clones were chosen each diluted in 3x96 w/p.
- At confluence the 15x96 w/p were duplicated in 15 white plates. 3 ½ hours before measurements, medium was replaced with 50 µl/well of tyrode (2 mM Ca<sup>2+</sup> and coelenterazine 10 µM).
- Second selection was done with 10 µM ATP monitoring the kinetics and then cells were lysed with TRITON X-100. CCD camera conditions: low sensitivity, integration time 1 second reading for 30 seconds for the ATP measurement followed by 30 seconds for TRITON X-100.
- Four limiting dilutions of the best clone selected were performed, 0.3 cells per well in 10x96 w/p.
- The final clone was chosen after the 4th LD selected with ATP 0.25 µM, coelenterazine 5 µM.
- Complete optimization of the assay was performed on the best responding clone.

#### CCD Camera Measurement parameters:

CHO cells are seeded at different cell densities in 384MTP (500, 750, 1,000, 1,500 cells/well) in growth media supplemented as above and measured with a CCD camera 24 hours and 48 hours after plating. Prior to experiments growth medium is removed and cells are loaded with Tyrode buffer plus coelenterazine at 37°C for 3 hours. Luminescence is finally monitored by CCD camera after the addition of the agonist (30 sec. kinetic).

#### **Fluorometric Imaging Plate Reader (FLIPR®) Measurements**

##### FLIPR<sup>3</sup> Settings for Assays standard protocol for luminescence detection

- 384 white wall clear bottom plates
- cell plating 24 hrs before the experiment
- medium removal

15

- addition of tyrode plus coelenterazine 25  $\mu$ l/well
- incubation 4 hrs at 37°C
- experiments run at FLIPR<sup>3</sup>: compound (2X) injection in tyrode buffer (25  $\mu$ l/well).

5 All parameter values are the instrumentation default values, except for the following:

**Pre-assay steps:**

1) Camera configuration:

Exposure length = 0.7

10 Camera gain = 200

2) Sequence parameters:

Dispense 384 well head

Height = 30  $\mu$ l

Speed = 25  $\mu$ l/sec

15 FLIPR<sup>TETRA</sup> Settings for Assays standard protocol for luminescence detection

- 384 white wall clear bottom plates
- cell plating 24 hrs before the experiment
- medium removal
- 20 • addition of tyrode plus coelenterazine 25  $\mu$ l/well
- incubation for 4 hrs at 37°C
- experiments run at FLIPR<sup>TETRA</sup>: compound (2X) injection in tyrode buffer (25  $\mu$ l/well).

25 All parameter values are the instrumentation default values, except for the following:

**Set up read mode:**

1) Camera configuration:

Camera Gain = 200

Exposure time = 0.50

2) Sequence parameters:

Height = 30  $\mu$ l

Speed = 25  $\mu$ l/sec

5 **Reference Compounds:**

ATP (Sigma, A-7699) was dissolved in H<sub>2</sub>O at a concentration of 100 mM and stored in aliquots at -20°C. Working solution was freshly prepared in tyrode buffer.

10 **Tyrode Buffer composition:** NaCl 130 mM, KCl 5 mM, CaCl<sub>2</sub> 2 mM, MgCl<sub>2</sub> 1 mM, NaHCO<sub>3</sub> 5 mM e HEPES 20 mM, pH 7.4.

**DESCRIPTION OF THE DRAWINGS**

Fig. 1: Re-test of mutant colonies with three calcium concentrations.

Fig. 2: In vitro Transcription & Translation. Measurement of light emission upon 5 pM calcium injection.

15 Fig. 3: In vitro Transcription & Translation. Measurement of light emission upon 1 mM calcium injection.

Fig. 4: Kinetics of the measurement of light emission upon 1 mM calcium injection for the recombinant photoproteins.

20 Fig. 5: Calcium dose-response curve of the recombinant photoprotein 25N03b.

Fig. 6: Peak light intensity from recombinant photoproteins upon 1 mM calcium injection.

Fig. 7: Kinetics of 10 mM ATP response at the CCD camera for the CHOK1/mito25N03b cell line.

25 Fig. 8: ATP dose-response curve of the CHOK1/mito25N03b cell line.

**EXAMPLES**

**1. Generation of a Randomly Mutagenized Library and Screening**

The Random mutant Library was obtained by using the GeneMorph II

Random Mutagenesis kit (Stratagene). In order to achieve a high mutation rate two different initial amounts of target DNA were used: 0.1 ng and 0.01 ng. A total of 83305 bacterial colonies were tested for luminescence activity. Of these, 1089 were positive and therefore had bioluminescent characteristics.

5 The best colonies were picked, for a total of 289 colonies, and of these, 16 resulted best after a re-test. Finally 8 colonies were chosen and analysed.

Figure 1 shows the results obtained in a three test-point  $\text{CaCl}_2$  dose-response curve obtained with the 8 mutants.

## 2. Photoprotein assay

10 5  $\mu\text{l}$  of the translation mixture were directly mixed with 95  $\mu\text{l}$  of PBS solution in a 96 well plate which was mounted into the Luminometer (Berthold). To trigger photoprotein light emission, a 5 pM  $\text{CaCl}_2$  solution was injected into the well and luminescence recorded for 10 seconds.

The results of the in vitro transcription and translation of the DNA of the  
15 8 mutants are shown in Fig. 2.

A new in vitro transcription and translation experiment was carried out with the best responding mutant, 25N03b (sequence ID n°15), and with the Acquorin photoprotein (Fig. 3) in order to have a comparison of the light emission upon the injection of 1mM  $\text{CaCl}_2$  solution.

## 20 3. Recombinant Photoprotein and Calcium concentration curve

Recombinant photoproteins corresponding to some mutants were produced under native conditions following a small scale purification protocol. Light emission was measured upon 1 mM calcium injection and the corresponding kinetics are shown in Fig. 4.

25 The recombinant mutant photoprotein, corresponding to clone 25N03b, was better characterized with a complete calcium dose-response curve, which can be seen in Fig. 5.

In another experiment, the recombinant photoprotein 25N03b was



compared to recombinant Aequorin. The light emission recorded upon 1 mM  $\text{CaCl}_2$  injection was surprisingly higher in the case of the 25N03b mutant as shown in Fig. 6.

#### 4. Cell-based functional assays

4.1 The CHOmito25N03b-expressing clone (CHOK1/mito25N03b) has been obtained by transfection of CHO-K1 cells (Materials and Methods). 48 hours after transfection the cells were trypsinized and plated into 10x96 MTP (Microtiter Plates) in complete MEM. At confluence, the 10x96 MTP were duplicated using MATRIX (Hudson, NH, USA) in 10x96 white MTP.

3 hours before measurement the medium was replaced with 50  $\mu\text{l}$ /well of tyrode buffer 2 mM  $\text{Ca}^{2+}$  and 10  $\mu\text{M}$  coelenterazine. The clones were selected on the basis of their functional response (luminescent signal) to ATP, which is known to stimulate the CHO endogenous receptor P2Y and to rise the cytoplasmic  $\text{Ca}^{2+}$  concentration. At the end of each experiment, cells were lysed by perfusion of a solution containing TritonX-100. The active photoprotein was reconstituted incubating the cells with 10  $\mu\text{M}$  coelenterazine diluted in tyrode buffer containing 2 mM  $\text{Ca}^{2+}$ , in the dark, at 37°C, in a 5%  $\text{CO}_2$  atmosphere for 3 hrs. For light emission measurement, cells were lysed in the presence of calcium and the emitted luminescence recorded. The number of photons emitted during the first 30 seconds was integrated by a CCD camera and visualized on the screen. Cells transfected with an empty plasmid or untransfected did not increase photon-emission. To detect changes in calcium concentrations, 10  $\mu\text{M}$  ATP was injected and the kinetics of the response determined. The curve obtained is shown in Fig. 7.

The final clone was seeded in 384 w/p and tested with increasing ATP concentrations as shown in the dose response curve in Fig. 8.

4.2 The CHOK1/mito25N03b cell line was transfected with a G-protein coupled receptor, the Adenosine A3 receptor, and with a chimeric  $\text{G}\alpha$  protein,

in order to switch the signal to the PLC/IP pathway. A stable cell line was generated (from now on referred as CHOK1/mito25N03b /A3 clone).

Upon stimulation with its agonist, the A3 receptor induces an increase in intracellular calcium concentration which is measured by mito25N03b  
5 luminescence.

4.3 The final clones of the CHO cell lines expressing mito25N03b and the human Adenosine A3 receptor were grown to 80-95% confluence in tissue culture flasks and harvested by trypsinization. Cells were dispensed at different cell densities in 384 w/p in growth medium (DMEM/F12 containing  
10 10% Foetal Bovine Serum) and incubated for 24 h and 48h at 37°C in a humidified incubator at 5% CO<sub>2</sub>. On the day of the experiment, the culture medium was removed and, for luminescence experiments, cells were loaded with 5 µM coelenterazine for 3h, at 37°C, 5% CO<sub>2</sub>. Calcium response was stimulated by addition of different concentrations of ATP to each well. The  
15 kinetics of flash luminescence was followed using a CCD camera, which injects reagents and records light emission from each single well.

The agonist and antagonist were diluted in tyrode buffer at different concentrations. Approximately 25 µl of these solutions were separately injected into each well and the response measured with the CCD camera  
20 instrumentation. The emitted light was immediately recorded at different time intervals.

#### 5. Cell-based fluorescence assays at the FLIPR<sup>384</sup>

The CHOK1/mito25N03b/A3 are tested at FLIPR<sup>384</sup> by measuring the fluorescence signal induced by the activation of the transfected receptor.

25 The cells are incubated with the Calcium assay kit (Molecular Devices Corporation, Sunnyvale, CA, USA).

These fluorescence experiments are carried out to evaluate the luminescence measured with the FLIPR instrumentation.

## REFERENCES

1. Kendall, J.M., and Badminton, M.N. (1998) *Aequorea victoria* bioluminescence moves into an exciting new era. Trends Biotechnology. 16(5):216-24.
- 5 2. Campbell, A.K., Hallet, R.A., Daw, M.E., Ryall, R.C., Hart and Herring P.J. (1981) Application of the photoprotein obelin to the measurement of free  $\text{Ca}^{++}$  in cells. In Bioluminescence and Chemiluminescence, basic Chemistry and Analytical applications (Edited by M.A. deLuca and W.D. McElroy), pp. 601-607. Academy Press, New York.
- 10 3. Herring, P.J. (1979) Some features of the bioluminescence of the radiolarian *Thalassicola* sp. Mar. Biol. 53, 213-216.
4. Shimomura, O., Johnson F.H., and Saiga, Y (1962) Extraction, purification and properties of aequorin, a bioluminescent protein from the luminous hydromedusan, *Aequorea*. J. Cell. Comp. Physiol. 59,223-239.
- 15 5. Shimomura, O., Johnson F.H., and Saiga, Y (1963) Further data on the bioluminescent protein, aequorin. J. Cell. Comp. Physiol. 62, 1-8.
6. Morin, J.G. and Hastings J.W. (1971) Biochemistry of the bioluminescence of colonial hydroids and other coelenterates. J. Cell. Physiol. 77, 305-311.
- 20 7. Shimomura, O., Johnson, F.H. and Saiga, Y. (1963) Extraction and properties of halistaurin, a bioluminescent protein from the hydromedusan *Halistaura*. J. Cell. Physiol. 62, 9-15.
8. Shimomura, O., and Shimomura, A. (1985) Halistaurin, phialidin and modified forms of aequorin as  $\text{Ca}^{++}$  indicator in biological systems. Biochem. J. 228,745-749.
- 25 9. Levine, L.D., and Ward, W.W. (1982) Isolation and characterization of a photoprotein "phialidin" and a spectrally unique green-fluorescent protein from the bioluminescent jellyfish *Phialidium gregarium*. Comp. Biochem.

Physiol. 72B,77-85.

10. Morin, J.G. and Hastings (1971) Energy transfer in a bioluminescent system. J. Cell. Physiol. 77, 313-318.
11. Campbell, A.K. (1974) Extraction, partial purification and properties of  
5 obelin the calcium-activated protein from the hydroid *Obelia geniculata*.  
Biochem.J. 143,411-418.
12. Ward, W.W. and Selinger (1974) Extraction and purification of  
calcium-activated photoprotein from the ctenophores *Mnemiopsis sp.* and *Beroë ovata*. Biochemistry 13, 1491-1499.
- 10 13. Ward, W.W. and Seliger H.H. (1974) Properties of mnemiopsin, and  
berovin, calcium-activated photoproteins from the ctenophores *Mnemiopsis*  
*sp.* and *Beroë ovata*. Biochemistry 13, 1500-1510.
14. Johnson, F.H. and Shimomura, O. (1978) Introduction to the  
bioluminescence of medusae, with special reference to the photoprotein  
15 aequorin. Methods Enzymol. 57,271-291.
15. Illarionov B.A., Bondar V.S., Illarionova V.A., Vysotski E.S. Sequence  
of the cDNA encoding the  $\text{Ca}^{++}$ -activated photoprotein obelin from the  
hydroid polyp *Obelia longissima*. Gene. 1995 14;153(2):273-4.
16. Blinks, J.R., Weir, W.G., Hess, P. and Prendergast, F.G. (1982).  
20 Measurement of  $\text{Ca}^{++}$  concentrations in living cells. Prog. Biophys. Mol. Biol.  
40,1-114.
17. Markova S.V., Vysotski E.S., Blinks J.R., Burakova L.P., Wang B.C.,  
Lee J., (2002) Obelin from the bioluminescent marine hydroid *Obelia*  
*geniculata*: cloning, expression; and comparison of some properties with those  
25 of other  $\text{Ca}^{2+}$ -regulated photoproteins. Biochemistry. 2002 Feb  
19;41(7):2227-36.
18. Inouye S., Tsuji F.I. (1993) Cloning and sequence analysis of cDNA for  
the  $\text{Ca}(2+)$ -activated photoprotein, clytin. FEBS Lett. Jan 11;315(3):343-6.

19. Tsuji F.I., Ohmiya Y., Fagan T.F., Toh H., Inouye S. (1995) Molecular evolution of the  $\text{Ca}^{2+}$ -binding photoproteins of the Hydrozoa. *Photochem Photobiol.* Oct 62(4):657-61.
20. Rizzuto, R., Simpson, A.W.M., Brini, M. and Pozzan, T. (1992) Rapid changes of mitochondrial  $\text{Ca}^{2+}$  revealed by specifically targeted recombinant aequorin. *Nature*, 358, 325-328.
21. Rizzuto, R., Brini, M., Murgia, M. and Pozzan, T. (1993) Microdomains with high  $\text{Ca}^{2+}$  close to  $\text{IP}_3$ -sensitive channels that are sensed by neighbouring mitochondria. *Science*, 262, 744-747.
22. Rizzuto, R., Bastianutto, C., Brini, M., Murgia, M. and Pozzan, T. (1994) Mitochondrial  $\text{Ca}^{2+}$  homeostasis in intact cells. *J. Cell Biol.*, 126, 1183-1194.

# CLAIMS

1. Isolated photoprotein containing an amino acid sequence which:

a) is able to bind coelenterazine and calcium, producing

bioluminescence;

b) is identical by at least 90% to SEQ ID NO: 1 (Clytin);

c) in sequence alignment with SEQ ID 1 (Clytin), presents one of the following single or multiple substitutions (the residue positions are referred to SEQ ID NO: 1):

i) C<sub>54</sub>→S;

ii) S<sub>132</sub>→C;

iii) K<sub>48</sub>→R, N<sub>195</sub>→D;

iv) Q<sub>68</sub>→R, A<sub>90</sub>→V, T<sub>184</sub>→I;

v) Y<sub>82</sub>→F, K<sub>110</sub>→N, F<sub>125</sub>→L, S<sub>149</sub>→R;

vi) G<sub>142</sub>→C;

vii) I<sub>53</sub>→V, S<sub>149</sub>→R;

viii) N<sub>18</sub>→D, I<sub>40</sub>→V, K<sub>56</sub>→R,

a functional derivative or fragment thereof.

2. The photoprotein of claim 1, containing an amino acid sequence

identical by at least 95% to SEQ ID NO: 1.

3. The photoprotein of claim 2, containing an amino acid sequence

identical by at least 98% to SEQ ID NO: 1.

4. The photoprotein of claim 3, containing an amino acid sequence which

is selected from the group consisting of SEQ ID NO: 2, 3, 4, 5, 6, 7, 8, 9.

5. A photoprotein according to claims 1-4, wherein said amino acid

sequence is fused to a mitochondrial target sequence.

6. An isolated polynucleotide encoding a photoprotein according to claims

1-5.



7. The polynucleotide of claim 6, having the sequence of SEQ ID NO: 10, 11, 12, 13, 14, 15, 16, 17.
8. An expression vector containing a polynucleotide according to anyone of claims 6-7.
- 5 9. A prokaryotic or eukaryotic host cell containing the vector of claim 8.
10. A mammalian host cell according to claim 9.
11. A method in vitro for detecting changes in intracellular calcium concentration which comprises:
- a) providing a cell expressing a photoprotein according to claims 1-5;
  - 10 b) contacting the cell with an agent stimulating calcium influx or calcium release from intracellular stores;
  - c) detecting the photoprotein bioluminescence.
12. A method of screening compounds modulating intracellular calcium concentration, which comprises:
- 15 a) providing a cell expressing a photoprotein of claims 1-5;
  - b) contacting the cell with the candidate compound;
  - c) detecting the bioluminescence of the photoprotein.
13. A method according to claims 12 or 13, which is carried out in a high-throughput format.
- 20 14. A method according to claim 13, which is carried out with a high throughput optical screening apparatus suited for multi-sample analysis.
15. The use of a photoprotein according to claims 1-5 as intracellular calcium indicator.
16. The use of a photoprotein according to claim 15 in a cell-based high
- 25 throughput assay.
17. The use of a photoprotein according to claims 1-5 for the preparation of a diagnostic composition.

25

**ABSTRACT****PHOTOPROTEINS WITH ENHANCED BIOLUMINESCENCE AND  
ASSAYS USING THE SAME**

5

The present invention relates to photoproteins with enhanced bioluminescence obtained by mutagenesis of clytin, to their use as intracellular calcium indicators and in cell-based assays.

1  
SEQUENCE LISTING

5 <110> AXXAM SRL

10 <120> photoproteins with enhanced bioluminescence and assays using the same

15 <130> 1489EUR

20 <160> 22

25 <170> PatentIn version 3.1

30 <210> 1  
<211> 196  
<212> PRT  
<213> Clytia gregaria

35 <400> 1

Met Ala Asp Thr Ala Ser Lys Tyr Ala Val Lys Leu Arg Pro Asn Phe  
1 5 10 15

40 Asp Asn Pro Lys Trp Val Asn Arg His Lys Phe Met Phe Asn Phe Leu  
20 25 30

45 Asp Ile Asn Gly Asp Gly Lys Ile Thr Leu Asp Glu Ile Val Ser Lys  
35 40 45

50 Ala Ser Asp Asp Ile Cys Ala Lys Leu Gly Ala Thr Pro Glu Gln Thr  
50 55 60

55 Lys Arg His Gln Asp Ala Val Glu Ala Phe Phe Lys Lys Ile Gly Met  
65 70 75 80

60 Asp Tyr Gly Lys Glu Val Glu Phe Pro Ala Phe Val Asp Gly Trp Lys  
85 90 95

Glu Leu Ala Asn Tyr Asp Leu Lys Leu Trp Ser Gln Asn Lys Lys Ser  
100 105 110

2

Leu Ile Arg Asp Trp Gly Glu Ala Val Phe Asp Ile Phe Asp Lys Asp  
115 120 125

5 Gly Ser Gly Ser Ile Ser Leu Asp Glu Trp Lys Ala Tyr Gly Arg Ile  
130 135 140

10 Ser Gly Ile Cys Ser Ser Asp Glu Asp Ala Glu Lys Thr Phe Lys His  
145 150 155 160

15 Cys Asp Leu Asp Asn Ser Gly Lys Leu Asp Val Asp Glu Met Thr Arg  
165 170 175

Gln His Leu Gly Phe Trp Tyr Thr Leu Asp Pro Asn Ala Asp Gly Leu  
180 185 190

20 Tyr Gly Asn Phe Val Pro  
195

25 <210> 2  
<211> 198  
<212> PRT  
30 <213> Unknown

35 <220>  
<223> Clytin mutant: mutClyK1  
<400> 2

40 Met Ala Asp Thr Ala Ser Lys Tyr Ala Val Lys Leu Arg Pro Asn Phe  
1 5 10 15

45 Asp Asn Pro Lys Trp Val Asn Arg His Lys Phe Met Phe Asn Phe Leu  
20 25 30

50 Asp Ile Asn Gly Asp Gly Lys Ile Thr Leu Asp Glu Ile Val Ser Lys  
35 40 45

Ala Ser Asp Asp Ile Ser Ala Lys Leu Gly Ala Thr Pro Glu Gln Thr  
50 55 60

55 Lys Arg His Gln Asp Ala Val Glu Ala Phe Phe Lys Lys Ile Gly Met  
65 70 75 80

60 Asp Tyr Gly Lys Glu Val Glu Phe Pro Ala Phe Val Asp Gly Trp Lys  
85 90 95

3

Glu Leu Ala Asn Tyr Asp Leu Lys Leu Trp Ser Gln Asn Lys Lys Ser  
100 105 110

5 Leu Ile Arg Asp Trp Gly Glu Ala Val Phe Asp Ile Phe Asp Lys Asp  
115 120 125

10 Gly Ser Gly Ser Ile Ser Leu Asp Glu Trp Lys Ala Tyr Gly Arg Ile  
130 135 140

15 Ser Gly Ile Cys Ser Ser Asp Glu Asp Ala Glu Lys Thr Phe Lys His  
145 150 155 160

Cys Asp Leu Asp Asn Ser Gly Lys Leu Asp Val Asp Glu Met Thr Arg  
165 170 175

20 Gln His Leu Gly Phe Trp Tyr Thr Leu Asp Pro Asn Ala Asp Gly Leu  
180 185 190

25 Tyr Gly Asn Phe Val Pro  
195

30 <210> 3

<211> 198

<212> PRT

35 <213> Unknown

40 <220>

<223> Clytin mutant: mutClyK4

<400> 3

45 Met Ala Asp Thr Ala Ser Lys Tyr Ala Val Lys Leu Arg Pro Asn Phe  
1 5 10 15

50 Asp Asn Pro Lys Trp Val Asn Arg His Lys Phe Met Phe Asn Phe Leu  
20 25 30

55 Asp Ile Asn Gly Asp Gly Lys Ile Thr Leu Asp Glu Ile Val Ser Lys  
35 40 45

Ala Ser Asp Asp Ile Cys Ala Lys Leu Gly Ala Thr Pro Glu Gln Thr  
50 55 60

60 Lys Arg His Gln Asp Ala Val Glu Ala Phe Phe Lys Lys Ile Gly Met  
65 70 75 80

4

Asp Tyr Gly Lys Glu Val Glu Phe Pro Ala Phe Val Asp Gly Trp Lys  
85 90 95

5 Glu Leu Ala Asn Tyr Asp Leu Lys Leu Trp Ser Gln Asn Lys Lys Ser  
100 105 110

10 Leu Ile Arg Asp Trp Gly Glu Ala Val Phe Asp Ile Phe Asp Lys Asp  
115 120 125

15 Gly Ser Gly Cys Ile Ser Leu Asp Glu Trp Lys Ala Tyr Gly Arg Ile  
130 135 140

Ser Gly Ile Cys Ser Ser Asp Glu Asp Ala Glu Lys Thr Phe Lys His  
145 150 155 160

20 Cys Asp Leu Asp Asn Ser Gly Lys Leu Asp Val Asp Glu Met Thr Arg  
165 170 175

25 Gln His Leu Gly Phe Trp Tyr Thr Leu Asp Pro Asn Ala Asp Gly Leu  
180 185 190

30 Tyr Gly Asn Phe Val Pro  
195

<210> 4

35 <211> 198

<212> PRT

40 <213> Unknown

<220>

45 <223> Clytin mutant: 1F10 mutant

<400> 4

50 Met Ala Asp Thr Ala Ser Lys Tyr Ala Val Lys Leu Arg Pro Asn Phe  
1 5 10 15

55 Asp Asn Pro Lys Trp Val Asn Arg His Lys Phe Met Phe Asn Phe Leu  
20 25 30

Asp Ile Asn Gly Asp Gly Lys Ile Thr Leu Asp Glu Ile Val Ser Arg  
35 40 45

60 Ala Ser Asp Asp Ile Cys Ala Lys Leu Gly Ala Thr Pro Glu Gln Thr  
50 55 60



5

Lys Arg His Gln Asp Ala Val Glu Ala Phe Phe Lys Lys Ile Gly Met  
65 70 75 80

5 Asp Tyr Gly Lys Glu Val Glu Phe Pro Ala Phe Val Asp Gly Trp Lys  
85 90 95

10 Glu Leu Ala Asn Tyr Asp Leu Lys Leu Trp Ser Gln Asn Lys Lys Ser  
100 105 110

15 Leu Ile Arg Asp Trp Gly Glu Ala Val Phe Asp Ile Phe Asp Lys Asp  
115 120 125

Gly Ser Gly Ser Ile Ser Leu Asp Glu Trp Lys Ala Tyr Gly Arg Ile  
130 135 140

20 Ser Gly Ile Cys Ser Ser Asp Glu Asp Ala Glu Lys Thr Phe Lys His  
145 150 155 160

25 Cys Asp Leu Asp Asn Ser Gly Lys Leu Asp Val Asp Glu Met Thr Arg  
165 170 175

30 Gln His Leu Gly Phe Trp Tyr Thr Leu Asp Pro Asn Ala Asp Gly Leu  
180 185 190

Tyr Gly Asp Phe Val Pro  
195

35

<210> 5

<211> 198

40

<212> PRT

<213> Unknown

45

<220>

<223> Clytin mutant: 1H7 mutant

50

<400> 5

Met Ala Asp Thr Ala Ser Lys Tyr Ala Val Lys Leu Arg Pro Asn Phe  
1 5 10 15

55

Asp Asn Pro Lys Trp Val Asn Arg His Lys Phe Met Phe Asn Phe Leu  
20 25 30

60

Asp Ile Asn Gly Asp Gly Lys Ile Thr Leu Asp Glu Ile Val Ser Lys  
35 40 45

6

Ala Ser Asp Asp Ile Cys Ala Lys Leu Gly Ala Thr Pro Glu Gln Thr  
50 55 60

5 Lys Arg His Arg Asp Ala Val Glu Ala Phe Phe Lys Lys Ile Gly Met  
65 70 75 80

10 Asp Tyr Gly Lys Glu Val Glu Phe Pro Val Phe Val Asp Gly Trp Lys  
85 90 95

15 Glu Leu Ala Asn Tyr Asp Leu Lys Leu Trp Ser Gln Asn Lys Lys Ser  
100 105 110

20 Leu Ile Arg Asp Trp Gly Glu Ala Val Phe Asp Ile Phe Asp Lys Asp  
115 120 125

Gly Ser Gly Ser Ile Ser Leu Asp Glu Trp Lys Ala Tyr Gly Arg Ile  
130 135 140

25 Ser Gly Ile Cys Ser Ser Asp Glu Asp Ala Glu Lys Thr Phe Lys His  
145 150 155 160

30 Cys Asp Leu Asp Asn Ser Gly Lys Leu Asp Val Asp Glu Met Thr Arg  
165 170 175

Gln His Leu Gly Phe Trp Tyr Ile Leu Asp Pro Asn Ala Asp Gly Leu  
180 185 190

35 Tyr Gly Asn Phe Val Pro  
195

40 <210> 6  
<211> 198

45 <212> PRT  
<213> Unknown

50 <220>  
<223> Clytin mutant: 1C12 mutant

55 <400> 6

Met Ala Asp Thr Ala Ser Lys Tyr Ala Val Lys Leu Arg Pro Asn Phe  
1 5 10 15

60 Asp Asn Pro Lys Trp Val Asn Arg His Lys Phe Met Phe Asn Phe Leu  
20 25 30

7

Asp Ile Asn Gly Asp Gly Lys Ile Thr Leu Asp Glu Ile Val Ser Lys  
35 40 45

5 Ala Ser Asp Asp Ile Cys Ala Lys Leu Gly Ala Thr Pro Glu Gln Thr  
50 55 60

10 Lys Arg His Gln Asp Ala Val Glu Ala Phe Phe Lys Lys Ile Gly Met  
65 70 75 80

15 Asp Phe Gly Lys Glu Val Glu Phe Pro Ala Phe Val Asp Gly Trp Lys  
85 90 95

Glu Leu Ala Asn Tyr Asp Leu Lys Leu Trp Ser Gln Asn Asn Lys Ser  
100 105 110

20 Leu Ile Arg Asp Trp Gly Glu Ala Val Phe Asp Ile Leu Asp Lys Asp  
115 120 125

25 Gly Ser Gly Ser Ile Ser Leu Asp Glu Trp Lys Ala Tyr Gly Arg Ile  
130 135 140

30 Ser Gly Ile Cys Arg Ser Asp Glu Asp Ala Glu Lys Thr Phe Lys His  
145 150 155 160

35 Cys Asp Leu Asp Asn Ser Gly Lys Leu Asp Val Asp Glu Met Thr Arg  
165 170 175

Gln His Leu Gly Phe Trp Tyr Thr Leu Asp Pro Asn Ala Asp Gly Leu  
180 185 190

40 Tyr Gly Asn Phe Val Pro  
195

45 <210> 7

<211> 198

<212> PRT

50 <213> Unknown

55 <220>

<223> Clytin mutant: 25N03b mutant

<400> 7

60 Met Ala Asp Thr Ala Ser Lys Tyr Ala Val Lys Leu Arg Pro Asn Phe  
1 5 10 15

8

Asp Asn Pro Lys Trp Val Asn Arg His Lys Phe Met Phe Asn Phe Leu  
20 25 30

5 Asp Ile Asn Gly Asp Gly Lys Ile Thr Leu Asp Glu Ile Val Ser Lys  
35 40 45

10 Ala Ser Asp Asp Ile Cys Ala Lys Leu Gly Ala Thr Pro Glu Gln Thr  
50 55 60

15 Lys Arg His Gln Asp Ala Val Glu Ala Phe Phe Lys Lys Ile Gly Met  
65 70 75 80

20 Asp Tyr Gly Lys Glu Val Glu Phe Pro Ala Phe Val Asp Gly Trp Lys  
85 90 95

25 Glu Leu Ala Asn Tyr Asp Leu Lys Leu Trp Ser Gln Asn Lys Lys Ser  
100 105 110

30 Leu Ile Arg Asp Trp Gly Glu Ala Val Phe Asp Ile Phe Asp Lys Asp  
115 120 125

35 Gly Ser Gly Ser Ile Ser Leu Asp Glu Trp Lys Ala Tyr Cys Arg Ile  
130 135 140

40 Ser Gly Ile Cys Ser Ser Asp Glu Asp Ala Glu Lys Thr Phe Lys His  
145 150 155 160

45 Cys Asp Leu Asp Asn Ser Gly Lys Leu Asp Val Asp Glu Met Thr Arg  
165 170 175

50 Gln His Leu Gly Phe Trp Tyr Thr Leu Asp Pro Asn Ala Asp Gly Leu  
180 185 190

55 Tyr Gly Asn Phe Val Pro  
195

<210> 8

<211> 198

<212> PRT

<213> Unknown

<220>

60 <223> Clytin mutant: 3C12 mutant

9

<400> 8

Met Ala Asp Thr Ala Ser Lys Tyr Ala Val Lys Leu Arg Pro Asn Phe  
1 5 10 15

Asp Asn Pro Lys Trp Val Asn Arg His Lys Phe Met Phe Asn Phe Leu  
20 25 30

Asp Ile Asn Gly Asp Gly Lys Ile Thr Leu Asp Glu Ile Val Ser Lys  
35 40 45

Ala Ser Asp Asp Val Cys Ala Lys Leu Gly Ala Thr Pro Glu Gln Thr  
50 55 60

Lys Arg His Gln Asp Ala Val Glu Ala Phe Phe Lys Lys Ile Gly Met  
65 70 75 80

Asp Tyr Gly Lys Glu Val Glu Phe Pro Ala Phe Val Asp Gly Trp Lys  
85 90 95

Glu Leu Ala Asn Tyr Asp Leu Lys Leu Trp Ser Gln Asn Lys Lys Ser  
100 105 110

Leu Ile Arg Asp Trp Gly Glu Ala Val Phe Asp Ile Phe Asp Lys Asp  
115 120 125

Gly Ser Gly Ser Ile Ser Leu Asp Glu Trp Lys Ala Tyr Gly Arg Ile  
130 135 140

Ser Gly Ile Cys Arg Ser Asp Glu Asp Ala Glu Lys Thr Phe Lys His  
145 150 155 160

Cys Asp Leu Asp Asn Ser Gly Lys Leu Asp Val Asp Glu Met Thr Arg  
165 170 175

Gln His Leu Gly Phe Trp Tyr Thr Leu Asp Pro Asn Ala Asp Gly Leu  
180 185 190

Tyr Gly Asn Phe Val Pro  
195

<210> 9

<211> 198

<212> PRT

<213> Unknown

10

&lt;220&gt;

&lt;223&gt; Clytin mutant: 6H22 mutant

5 &lt;400&gt; 9

Met Ala Asp Thr Ala Ser Lys Tyr Ala Val Lys Leu Arg Pro Asn Phe  
1 5 10 15

10

Asp Asp Pro Lys Trp Val Asn Arg His Lys Phe Met Phe Asn Phe Leu  
20 25 30

15

Asp Ile Asn Gly Asp Gly Lys Val Thr Leu Asp Glu Ile Val Ser Lys  
35 40 45

20

Ala Ser Asp Asp Ile Cys Ala Arg Leu Gly Ala Thr Pro Glu Gln Thr  
50 55 60

25

Lys Arg His Gln Asp Ala Val Glu Ala Phe Phe Lys Lys Ile Gly Met  
65 70 75 80

30

Asp Tyr Gly Lys Glu Val Glu Phe Pro Ala Phe Val Asp Gly Trp Lys  
85 90 95

Glu Leu Ala Asn Tyr Asp Leu Lys Leu Trp Ser Gln Asn Lys Lys Ser  
100 105 110

35

Leu Ile Arg Asp Trp Gly Glu Ala Val Phe Asp Ile Phe Asp Lys Asp  
115 120 125

40

Gly Ser Gly Ser Ile Ser Leu Asp Glu Trp Lys Ala Tyr Gly Arg Ile  
130 135 140

45

Ser Gly Ile Cys Ser Ser Asp Glu Asp Ala Glu Lys Thr Phe Lys His  
145 150 155 160

Cys Asp Leu Asp Asn Ser Gly Lys Leu Asp Val Asp Glu Met Thr Arg  
165 170 175

50

Gln His Leu Gly Phe Trp Tyr Thr Leu Asp Pro Asn Ala Asp Gly Leu  
180 185 190

55 Tyr Gly Asn Phe Val Pro  
195

60 &lt;210&gt; 10

&lt;211&gt; 600



11

&lt;212&gt; DNA

&lt;213&gt; Unknown

5

&lt;220&gt;

10

&lt;223&gt; Clytin mutant: mutClyK1\_dna

&lt;400&gt; 10

atggccgaca ccgcccagcaa gtacgccgtg aagctgaggc ccaacttcga caaccccaag 60

15

tgggtgaacc ggcacaagtt catgttcaac ttcttgga tcaacggcga cggcaagatc 120

accctggacg agatcgtgag caaggccagc gacgacatct gcgccaagct gggcgccacc 180

cccgagcaga ccaagagaca ccaggacgcc gtggaggcct tcttcaagaa gatcggcatg 240

20

gactacggca aggaggtgga gttccccgcc ttcttgga gctggaagga gctggccaac 300

taccacctga agctgtggag ccagaacaag aagagcctca tcagggactg gggcgaggcc 360

25

gtgttcgaca tcttcgacaa ggacggcage ggctgcatca gcctggatga gtggaaggcc 420

tacggcagaa tcagcggcat ctgcagcagc gacgaggacg ccgaaaagac cttcaagcac 480

tgcgacctgg acaacagcgg caagctggac gtggacgaga tgaccagaca gcacctggac 540

30

ttctggtaca ccttggaacc caatgccgac ggctgtacg gcaacttcgt gccttgataa 600

&lt;210&gt; 11

35

&lt;211&gt; 600

&lt;212&gt; DNA

&lt;213&gt; Unknown

40

&lt;220&gt;

45

&lt;223&gt; Clytin mutant: mutClyK1\_dna

&lt;400&gt; 11

atggccgaca ccgcccagcaa gtacgccgtg aagctgaggc ccaacttcga caaccccaag 60

50

tgggtgaacc ggcacaagtt catgttcaac ttcttgga tcaacggcga cggcaagatc 120

accctggacg agatcgtgag caaggccagc gacgacatct gcgccaagct gggcgccacc 180

55

cccgagcaga ccaagagaca ccaggacgcc gtggaggcct tcttcaagaa gatcggcatg 240

gactacggca aggaggtgga gttccccgcc ttcttgga gctggaagga gctggccaac 300

tacgacctga agctgtggag ccagaacaag aagagcctca tcagggactg gggcgaggcc 360

60

gtgttcgaca tcttcgacaa ggacggcage ggctgcatca gcctggatga gtggaaggcc 420

tacggcagaa tcagcggcat ctgcagcagc gacgaggacg ccgaaaagac cttcaagcac 480

12

tgcgacctgg acaacagcgg caagctggac gtggacgaga tgaccagaca gcacctgggc 540  
ttctggtaca ccctggaccc caatgccgac ggcctgtacg gcaacttcgt gccttgataa 600

5

&lt;210&gt; 12

&lt;211&gt; 600

10

&lt;212&gt; DNA

&lt;213&gt; Unknown

15

&lt;220&gt;

&lt;223&gt; Clytin mutant: 1F10 mutant\_dna

20

&lt;400&gt; 12

atggccgaca ccgccagcaa gtacgccgtg aagctgaggc ccaacttcga caaccccaag 60

tgggtgaacc ggcacaagtt catgttcaac ttcttgga tcaacggcga cggcaagatc 120

25

accctggacg agatcgtgag cagggccagc gacgacatct gcgccaagct gggcgccacc 180

cccgaacaga ccaagagaca ccaggacgcc gtggaggcct tcttcaagaa gatcggcatg 240

gactacggca aggaggtgga gttccccgcc ttcttgga gctggaagga gctggccaac 300

30

tacgacctga agctgtggag ccagaacaag aagagcctca tcagggaactg gggcgaggcc 360

gtgttcgaca tcttcgacaa ggacggcagc ggcagcatca gcctggatga gtggaaggcc 420

35

tacggcagaa tcagcggcat ctgcagcagc gacgaggacg ccgaaaagac cttcaagcac 480

tgcgacctgg acaacagcgg caagctggac gtggacgaga tgaccagaca gcacctgggc 540

ttctggtaca ccctggaccc caacgccgac ggcctgtacg gcgacttcgt gccttgataa 600

40

&lt;210&gt; 13

&lt;211&gt; 600

45

&lt;212&gt; DNA

&lt;213&gt; Unknown

50

&lt;220&gt;

&lt;223&gt; Clytin mutant: 1R7 mutant\_dna

55

&lt;400&gt; 13

atggccgaca ccgccagcaa gtacgccgtg aagctgaggc ccaacttcga caaccccaag 60

tgggtgaacc ggcacaagtt catgttcaat ttcttgga tcaacggcga cggcaagatc 120

60

accctggacg agatcgtgag caaggccagc gacgacatct gcgccaagct gggcgccacc 180

13

ccccgagcaga ccaagagaca ccgggacgcc gtggaggcct tcttcaagaa gatcggcatg 240  
gactacggca aggaggtgga gttccccgtc ttcgtggacg gctggaagga gctggccaac 300  
5 tacgacctga agctgtggag ccagaacaag aagagcctca tcagggactg gggcgaggcc 360  
gtgtttgaca tcttcgacaa ggacggcagc ggcagcatta gcctggatga gtggaaggcc 420  
10 tacggtagaa tcagcggcat ctgcagcagc gacgaggacg ccgaaaagac cttcaagcac 480  
tgcgacctgg acaacagcgg caagctggac gtggacgaga tgaccagaca gcacctgggc 540  
ttctggtaca tcctggaccc caacgccgac ggcctgtacg gcaacttcgt gccttgataa 600

15  
<210> 14  
<211> 600  
20 <212> DNA  
<213> Unknown

25  
<220>  
<223> Clytin mutant: 1C12 mutant\_dna

30 <400> 14  
atggccgaca ccgccagcaa gtacgccgtg aagctgaggc ccaacttcga caacccaag 60  
tggtgaacc ggcacaagtt catgttcaac ttcctggaca tcaacggcga cggcaagatc 120  
35 acctggacg agatcgtgag caaggccagc gacgacatct gcgccaaact gggcgccacc 180  
ccccgagcaga ccaagagaca ccaggacgcc gtggaggcct tcttcaagaa gatcggcatg 240  
gacttcggca aggaggtgga gttccccgcc ttcgtggacg gctggaagga gctggccaac 300  
40 tacgacctga agctgtggag ccagaacaat aagagcctca tcagggactg gggcgaggcc 360  
gtgttegaca tcctcgacaa ggacggcagc ggcagcatca gcctggatga gtggaaggcc 420  
45 tacggcagaa tcagcggcat ctgcagaagc gacgaggacg ccgaaaagac cttcaagcac 480  
tgcgacctgg acaacagcgg caagctggac gtggacgaga tgaccagaca gcacctgggc 540  
50 ttctggtaca ccttggaccc caacgccgac ggcctgtacg gcaacttcgt gccttgataa 600

<210> 15  
<211> 600  
55 <212> DNA  
<213> Unknown

60

14

&lt;220&gt;

&lt;223&gt; Clytin mutant: 25N03b mutant\_dna

5 <400> 15  
atggccgaca ccgccagcaa gtacgccgtg aagctgagge ccaacttcga caaccccaag 60  
tgggtgaacc ggcacaagtt catgttcaac ttcttgga tcaacggcga cggcaagatc 120  
10 accctggacg agatcgtgag caaggccage gacgacatct gcgccaagct gggcgccacc 180  
cccgagcaga ccaagagaca ccaggacgcc gtggaggcct tcttcaagaa gatcggcatg 240  
gactacggca aggaggtgga gttccccgcc ttcttgga cgtggaagga gctggccaac 300  
15 tacgacctga agctgtggag ccagaacdag aagagcctca tcagggactg gggcgaggcc 360  
gtgttcgaca tcttcgacaa ggacggcagc ggcagcatca gcctggatga gtggaaggcc 420  
20 tactgcagaa tcagcggcat ctgcagcagc gacgaggacg ccgaaaagac cttcaagcac 480  
tgcgacctgg acaacagcgg caagctggac gtggacgaga tgaccagaca gcacctgggc 540  
25 ttctggtaca ccctggaccc caacgccgac ggcctgtacg gcaacttcgt gccttgataa 600

&lt;210&gt; 16

&lt;211&gt; 600

&lt;212&gt; DNA

&lt;213&gt; Unknown

35

&lt;220&gt;

&lt;223&gt; Clytin mutant: 3C12 mutant\_dna

40

<400> 16  
atggccgaca ccgccagcaa gtacgccgtg aagctgagge ccaacttcga caaccccaag 60  
tgggtgaacc ggcacaagtt catgttcaac ttcttgga tcaacggcga cggcaagatc 120  
45 accctggacg agatcgtgag caaggccage gacgacgtct gcgccaagct gggcgccacc 180  
cccgagcaga ccaagagaca ccaggacgcc gtggaggcct tcttcaagaa gatcggcatg 240  
gactacggca aggaggtgga gttccccgcc ttcttgga cgtggaagga gctggccaac 300  
tacgacctga agctgtggag ccaaaacaag aagagcctca tcagggactg gggcgaggcc 360  
gtgttcgaca tcttcgacaa ggacggcagc ggcagcatca gcctggacga gtggaaggcc 420  
55 tacggcagaa tcagcggcat ctgcagaagc gacgaggacg ccgaaaagac cttcaagcac 480  
tgcgacctgg acaacagcgg caagctggac gtggacgaga tgaccagaca gcacctgggc 540  
60 ttctggtaca ccctggaccc caacgccgac ggcctgtacg gcaacttcgt gccttgataa 600

15

&lt;210&gt; 17

&lt;211&gt; 600

5 &lt;212&gt; DNA

&lt;213&gt; Unknown

10

&lt;220&gt;

&lt;223&gt; Clytin mutant: 6H22 mutant\_dna

15 &lt;400&gt; 17

atggccgaca ccgccagcaa gtacgccgtg aagctgaggg ccaacttcga cgaccccaag 60

tgggtgaacc ggcacaagtt catgttcaac ttcttgga tcaacggcga cggcaaggte 120

20 accctggacg agatcgtgag caaggccagc gacgacatct gcgccagget gggcgccacc 180

cccgagcaga ccaagagaca ccaggacgcc gtggaggcct tcttcaagaa gatcggcatg 240

25 gactacggca aagaggtgga gttccccgcc ttcttgga gctggaagga gctggccaac 300

tacgacctga agctgtggag ccagaacaag aagagcctca tcagggactg gggcgaggcc 360

gtgttcgaca tcttcgacaa ggacggcagc ggcagcatca gcctggatga gtggaaggcc 420

30 tacggcagaa tcagcggcat ctgcagcagc gacgaggacg ccgaaaagac cttcaagcac 480

tgcgacctgg acaacagcgg caagctggac gtggacgaga tgaccagaca gcacctgggc 540

35 ttctgggtaca ccttggaccc caacgccgac ggcctgtacg gcaacttcgt gccttgataa 600

&lt;210&gt; 18

&lt;211&gt; 32

40 &lt;212&gt; DNA

&lt;213&gt; Unknown

45

&lt;220&gt;

&lt;223&gt; synthetic primer

50

&lt;400&gt; 18

gatgacgacg acaagatggc cgacaccgcc ag 32

55 &lt;210&gt; 19

&lt;211&gt; 33

&lt;212&gt; DNA

60

&lt;213&gt; Unknown

16

&lt;220&gt;

&lt;223&gt; synthetic primer

5

&lt;400&gt; 19

gaggagaagc ccggtttatc aaggacacga agt

33

10

&lt;210&gt; 20

&lt;211&gt; 33

&lt;212&gt; DNA

15

&lt;213&gt; Unknown

20

&lt;220&gt;

&lt;223&gt; synthetic primer

25

&lt;400&gt; 20

tcgttgggat ccgccaccat ggccgacacc gcc

33

&lt;210&gt; 21

&lt;211&gt; 27

30

&lt;212&gt; DNA

&lt;213&gt; Unknown

35

&lt;220&gt;

&lt;223&gt; synthetic primer

40

&lt;400&gt; 21

gggccctcta gattatcaag gcacgaa

27

45

&lt;210&gt; 22

&lt;211&gt; 99

&lt;212&gt; DNA

50

&lt;213&gt; Homo sapiens

55

&lt;400&gt; 22

atgtccgtcc tgacgccgct gctgctgcgg ggcttgacag gctcggcccg gcggtccca

60

gtgccgcgcg ccaagatcca ttcgttgga tccgccacc


99

60




Sheet 1/8

FIG. 1




Sheet 2/8

FIG. 2




Sheet 3/8

FIG. 3




Sheet 4/8

FIG. 4




Sheet 5/8

FIG. 5



Sheet 6/8


FIG. 6






Sheet 7/8

FIG. 7



Sheet 8/8

FIG. 8



# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/EP2006/002172

International filing date: 09 March 2006 (09.03.2006)

Document type: Certified copy of priority document

Document details: Country/Office: EP  
Number: 06000171.6  
Filing date: 05 January 2006 (05.01.2006)

Date of receipt at the International Bureau: 20 June 2006 (20.06.2006)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

Europäisches Patentamt  
GD1European Patent Office  
DG1Office européen des brevets  
DG1

PCT/EP200 6 / 0 0 2 1 7 2

09.03.06

Bescheinigung

Certificate

Attestation

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

Patentanmeldung Nr.

Patent application No.

Demande de brevet n°

06000171.6 / EP06000171

The organization code and number of your priority application, to be used for filing abroad under the Paris Convention, is EP06000171

Der Präsident des Europäischen Patentamts;  
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets  
p.o.

R.C. van Dijk



Europäisches Patentamt  
GD1

European Patent Office  
DG1

Office européen des brevets  
DG1

PCT/EP200 6/ 0 0 2 1 7 2

09.03.06

Anmeldung Nr:  
Application no.: 06000171.6  
Demande no:

Anmeldetag:  
Date of filing: 05.01.06  
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

AXXAM S.r.l.  
Via Massena, 12/7  
20145 Milano/IT

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:  
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.  
If no title is shown please refer to the description.  
Si aucun titre n'est indiqué se referer à la description.)

Photoproteins with enhanced bioluminescence and assays using the same

In anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s) revendiquée(s)  
Staat/Tag/Aktenzeichen / State/Date/File no. / Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation / International Patent Classification / Classification internationale de brevets:

C07K14/435

Am Anmeldetag benannte Vertragsstaaten / Contracting states designated at date of filing / Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR